284 related articles for article (PubMed ID: 31754664)
1. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X
Zhang X; Thummuri D; He Y; Liu X; Zhang P; Zhou D; Zheng G
Chem Commun (Camb); 2019 Dec; 55(98):14765-14768. PubMed ID: 31754664
[TBL] [Abstract][Full Text] [Related]
2. Discovery of PROTAC BCL-X
Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
[TBL] [Abstract][Full Text] [Related]
3. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
Negi A; Voisin-Chiret AS
Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
[TBL] [Abstract][Full Text] [Related]
5. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
6. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
[TBL] [Abstract][Full Text] [Related]
7. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Novel BCL-X
Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
[TBL] [Abstract][Full Text] [Related]
9. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
[TBL] [Abstract][Full Text] [Related]
10. A selective BCL-X
Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
[TBL] [Abstract][Full Text] [Related]
11. Curcumin Combined with Thalidomide Reduces Expression of
Mohammadi Kian M; Salemi M; Bahadoran M; Haghi A; Dashti N; Mohammadi S; Rostami S; Chahardouli B; Babakhani D; Nikbakht M
Drug Des Devel Ther; 2020; 14():185-194. PubMed ID: 32021103
[TBL] [Abstract][Full Text] [Related]
12. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
[TBL] [Abstract][Full Text] [Related]
13. Physiological restraint of Bak by Bcl-xL is essential for cell survival.
Lee EF; Grabow S; Chappaz S; Dewson G; Hockings C; Kluck RM; Debrincat MA; Gray DH; Witkowski MT; Evangelista M; Pettikiriarachchi A; Bouillet P; Lane RM; Czabotar PE; Colman PM; Smith BJ; Kile BT; Fairlie WD
Genes Dev; 2016 May; 30(10):1240-50. PubMed ID: 27198225
[TBL] [Abstract][Full Text] [Related]
14. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
15. miR-326 targets antiapoptotic Bcl-xL and mediates apoptosis in human platelets.
Yu S; Huang H; Deng G; Xie Z; Ye Y; Guo R; Cai X; Hong J; Qian D; Zhou X; Tao Z; Chen B; Li Q
PLoS One; 2015; 10(4):e0122784. PubMed ID: 25875481
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases.
Josefsson EC; Vainchenker W; James C
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066573
[TBL] [Abstract][Full Text] [Related]
17. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest.
Kang S; Kang D; Bakhtiar Ul Islam SM; Je S; Kim JH; Song JJ
Cell Signal; 2015 Jun; 27(6):1214-24. PubMed ID: 25748050
[TBL] [Abstract][Full Text] [Related]
18. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
19. Bcl-x
Yan Y; Xie R; Zhang Q; Zhu X; Han J; Xia R
Platelets; 2019; 30(1):75-80. PubMed ID: 29125379
[TBL] [Abstract][Full Text] [Related]
20. BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer.
Ramesh P; Di Franco S; Atencia Taboada L; Zhang L; Nicotra A; Stassi G; Medema JP
Cell Rep; 2022 Feb; 38(7):110374. PubMed ID: 35172148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]